Part 2 Once the Dose Limiting Toxicity (DLT) is established, further enrollment will continue to expand that dose cohort (and any dose cohort below) for a maximum of 10 subjects for each of the dose levels (inclusive of subjects both in Part 1 and Part 2 of the study). After the completion of Part 1 of the study, patients will be screened during a period of 28 days to be eligible for this part of the study.